Seer
Seer develops innovative solutions that act as a gateway to the proteome. Their goal is to empower the scientific community with tools to achieve exceptional scienti?c outcomes. They do this by removing the technological barriers that stand between breakthrough ideas and the information that can make them a reality.
Latest Seer Content
Industry Insight
Pushing the Boundaries of Biological Discovery in Proteomics
Dr. Omid Farokhzad, chair and CEO at Seer, discusses how to achieve deep, unbiased and scalable analysis of the proteome at speed at ASMS 2024.
Webinar
Exposome Insights: Decoding Spaceflight and Aging With Proteomics
On-Demand
Join expert speakers, Dr. Christopher Mason of Weill Cornell Medicine, and Dr. Michael Roberts of Auburn University, for an enlightening discussion on the profound impacts of spaceflight on human biology and the unique molecular signatures of aging influenced by resistance training.
Webinar
Plasma Proteome Profiling for Lung Cancer Biomarker Discovery
On-Demand
In this webinar, you’ll hear how one of the largest multiomics observational studies to date has revealed lung cancer biomarkers from the blood plasma proteome. Our expert speakers will discuss how the research sheds new light on early-stage lung cancer diagnostics and clinical outcomes and showcase how multiomics approaches are key for characterizing complex diseases.
Product News
Seer ProteographTM Enables Unprecedented Genetic Marker Mapping for Proteogenomics Studies
Study demonstrates identification of protein altering variants for population-scale protein quantitative trait loci (pQTL) studies. Proteograph Product Suite enables scalable deep, unbiased proteomics by mass spectrometry.
Product News
Seer Launches the Proteograph XT Assay Kit
Seer’s Proteograph XT pushes the boundaries of biological discovery by enabling rapid proteomics across a range of sample types and species with unprecedented resolution and scale.
Industry Insight
Probing the Proteome With Engineered Nanoparticles
In this interview, Dr. Daniel Hornburg discusses how engineered nanoparticles could help to bridge the gap between proteomics and genomics and transform cancer diagnostics.
Advertisement
